The use of selective mTOR inhibitors on proliferating primary CLL and mouse CLL cells has highlighted the potential to inhibit translation elongation processes, and identifies a novel therapeutic target for patients with progressive CLL downstream of mTORC1. This evidence concerns the gene MTOR and B-cell chronic lymphocytic leukemia.